ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: biosimilars

Pharmaceutical Care Models, Tools for Treating Patients with Rheumatoid Arthritis

Louise Grech, BPharm (Hons), MPhil, MRPharmS, Victor Ferrito, BSc, MSc, PhD, CSci, Liberato Camilleri, BEd, MSc, PhD, Anthony Serracino Inglott, BPharm, PharmD, MRPharmS, & Lilian M. Azzopardi, BPharm (Hons), MPhil, PhD, MRPharmS  |  January 19, 2016

Rheumatoid arthritis (RA) can be defined as a chronic autoimmune systemic inflammatory condition characterized by symmetrical polyarthritis. Typically, patients present with pain, stiffness and warmth of the affected joints. The condition can result in extra-articular features, adding to disability, and may eventually lead to premature death, especially if not treated early and appropriately.1,2 Over the…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Drugspatient carepharmaceuticalRheumatoid arthritistherapyTreatment

How to Choose the xBest Course of Treatment to Manage Rheumatoid Arthritis

How to Choose the Best Course of Treatment to Manage Rheumatoid Arthritis

Karen Appold  |  January 19, 2016

Diagnosing rheumatoid arthritis (RA) early in the disease process is ideal, because treatments are more likely to be effective and less damage will occur. Guidelines from the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) state that using newer biologic medications, in addition to more aggressive dosing of traditional medications, is…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Managementpatient careRheumatoid arthritistherapyTreatment

U.S. Patent Office Rules Against Amgen Humira Challenge

Bill Berkrot  |  January 16, 2016

(Reuters)—U.S. patent officials on Thursday denied petitions by Amgen to review two formulation patents on AbbVie’s Humira (adalimumab), a potential setback in Amgen efforts to market a biosimilar version of the world’s top-selling prescription medicine. In June, Amgen, the world’s biggest biotechnology company, asked the U.S. Patent and Trademark Office for the review, arguing that…

Filed under:Drug Updates Tagged with:adalimumabAmgenBiologics & Biosimilars

Dr. Michael Weinblatt Discusses Current & Future RA Therapies

Richard Quinn  |  December 11, 2015

According to former ACR President Michael Weinblatt, MD, the future of drug therapies for patients with RA rests in the careful and intelligent prescription of current medications and treatment combinations, as well as better patient access through lower costs…

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:BiologicsBiologics & Biosimilarscombination therapydrug therapyMethotrexateRheumatoid Arthritis (RA)

Researchers Find Rheumatologists Are Prescribing Methotrexate Less Often to Treat RA

Richard Quinn  |  December 8, 2015

An analysis by former ACR President James O’Dell, MD, and colleagues shows that rheumatologists may be moving too quickly from methotrexate therapy to biologics when treating patients with RA…

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:BiologicsMethotrexaterheumatologist

Gene Expression Markers in T Cells Help Identify SLE Patient Subtypes

Lara C. Pullen, PhD  |  December 7, 2015

Researchers used T cell transcriptome analysis in a small-scale study, identifying gene expression of specific patient subtypes and finding that expression alteration of T cells may correlate with severity of SLE rather than its presentation…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:Biomarkersgenesystemic lupus erythematosus (SLE)T cell

Amgen Files for U.S. Approval of Biosimilar

Bill Berkrot  |  November 29, 2015

(Reuters)—Amgen Inc. on Wednesday said it filed with U.S. health regulators seeking approval to sell its first biosimilar drug, which would be a less expensive alternative to AbbVie’s Humira (adalimumab), the world’s top-selling prescription medicine. Amgen said its drug, ABP 501, has demonstrated clinical equivalence and comparable safety to Humira in late stage clinical trials…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabAmgenBiosimilarsFDAFood and Drug Administration

Advocate for Rheumatology with the ACR

From the College  |  November 18, 2015

Your voice is an essential part of the ACR’s advocacy efforts, and our new Legislative Action Center makes contacting your legislator easier than ever before…

Filed under:From the CollegeLegislation & AdvocacyProfessional Topics

Dr. St.Clair Reflects on Progress in Rheumatology

E. William St.Clair, MD  |  November 17, 2015

As a practicing rheumatologist, I have experienced the increasing payer and government involvement shaping our evolving healthcare system. New payment models, changes in health insurance coverage, the federal mandate for the adoption of electronic health records and the implementation of ICD-10 are recent changes that have rocked our world. Our patients are also paying the…

Filed under:President's PerspectiveResearch RheumWorkforce Tagged with:AC&RAdvocacyAmerican College of Rheumatology (ACR)GuidelinesPractice ManagementprogressResearchtransformation

Methotrexate Increases Risk of Recurrent Nonmelanoma Skin Cancer

Will Boggs, MD  |  November 4, 2015

NEW YORK (Reuters Health)—Methotrexate appears to increase the risk of recurrent nonmelanoma skin cancer (NMSC) in patients with rheumatoid arthritis (RA), according to a retrospective study. “We have known for some time that several of the immunosuppressive agents used to treat RA and inflammatory bowel disease (IBD) are also associated with an increased risk of…

Filed under:Drug Updates Tagged with:Cancerinflammatory bowel diseaseMethotrexatenonmelanoma skin cancer (NMSC)Rheumatiod arthritis

  • « Previous Page
  • 1
  • …
  • 25
  • 26
  • 27
  • 28
  • 29
  • …
  • 32
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences